Taylor & Francis Group
Browse
isum_a_1717534_sm9999.pdf (218.45 kB)

Factors Associated with Electronic Cigarette Use among Young Adults: The French “Trajectoires EpidéMiologiques en POpulation” (TEMPO) Cohort Study

Download (218.45 kB)
journal contribution
posted on 2020-01-30, 13:16 authored by Hala Aljandaleh, Camille Bolze, Fabienne El-Khoury Lesueur, Maria Melchior, Murielle Mary-Krause

Background: Electronic cigarettes (e-cigarettes) are sold in France since 2010 and have rapidly become popular. However, factors associated with e-cigarette use among young adults are not well known. Methods: We used data from the 2015 French TEMPO community based cohort study, restricted to current and former smokers with data on e-cigarette use (n=368 adults, 23-41years). Participants completed a self-administered questionnaire including information on family status, educational attainment, occupation and type of work contract, health problems, alcohol and cannabis use, electronic cigarette use, as well as perceptions of e-cigarettes. Use of traditional tobacco was assessed in 2011 and 2015. Data were analyzed using logistic regression models. Results: Among current and former smokers, 26.9% reported lifetime e-cigarettes use and 15.2% current use. Factors associated with lifetime use were: low socioeconomic position (OR=2.2; 95% CI=1.2-4.2), traditional cigarette use (OR associated with smoking in 2011 and 2015=13.1; 95% CI=5.2-32.6) and positive perceptions of e-cigarettes (OR = 4.4; 95% CI=2.4-8.1) as well as asthma (OR=2.1; 95% CI=0.9-4.9) and overweight/obesity (OR=2.5, 95% CI=0.9-6.9). Factors associated with current use were traditional cigarette smoking (OR associated with smoking in 2011 and 2015=3.9; 95% CI= 1.3-12.2) and positive perceptions of e-cigarettes (OR =4.4; 95% CI=2.3-8.4). Conclusions: Young adults who use e-cigarettes tend to persist in smoking traditional cigarettes. The conditions under which e-cigarette use can help individuals quit traditional tobacco products remain to be elucidated.

Funding

This work was supported by the French National Research Agency (ANR); French Institute for Public Health Research-IReSP (TGIR Cohortes); the French Inter-departmental Mission for the Fight against Drugs and Drug Addiction (MILDeCA); the French Institute of Cancer (INCa); and the Pfizer Foundation.

History